Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2008
Gonadotroph adenoma in multiple endocrine neoplasia type 1.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sztal-Mazer Shoshana, Topliss Duncan J, Simpson Richard W, Hamblin P Shane, Rosenfeld Jeffrey V, McLean Catriona A
Аннотация
OBJECTIVE: To describe a case of an in vivo follicle-stimulating hormone (FSH)-secreting gonadotroph adenoma in a man with multiple endocrine neoplasia type 1 (MEN 1) syndrome.
METHODS: We present a retrospective case description and a discussion of the related literature.
RESULTS: A 48-year-old man had progressively deteriorating visual acuity and bitemporal hemianopia, found to be attributable to a macroadenoma encircling both carotid arteries and compressing the optic chiasm. His libido and erectile function had been reduced for 2 years. The serum FSH level was substantially elevated at 31.1 IU/L (reference range, 1 to 10); alpha-subunit was elevated at 2.25 IU/L (reference range, 0.09 to 0.4); luteinizing hormone was normal at 4 IU/L (reference range, 1 to 10); total testosterone was low at 6.8 nmol/L (reference range, 9.5 to 35); and prolactin was slightly increased at 433 mU/L (reference range, 50 to 300). Transsphenoidal hypophysectomy was performed. Pituitary histopathologic examination showed a tumor with cytoplasmic granular FSH immunoreactivity. The patient had undergone parathyroidectomy for primary hyperparathyroidism 2 years before the current intervention. A family history of endocrine neoplasia was obtained of one sibling with a nonfunctioning pituitary adenoma, another sibling who had died of pancreatic carcinoma, and a third sibling, along with her son, who has primary hyperparathyroidism. Performance of genetic testing for MEN 1 revealed a nonsense mutation--R460X (nt7605C>T)--located on exon 10 of the MEN1 gene.
CONCLUSION: We report an unusual case of clearly high circulating immunoreactive FSH due to a functioning FSH-secreting gonadotroph adenoma in a man with the MEN 1 syndrome.
METHODS: We present a retrospective case description and a discussion of the related literature.
RESULTS: A 48-year-old man had progressively deteriorating visual acuity and bitemporal hemianopia, found to be attributable to a macroadenoma encircling both carotid arteries and compressing the optic chiasm. His libido and erectile function had been reduced for 2 years. The serum FSH level was substantially elevated at 31.1 IU/L (reference range, 1 to 10); alpha-subunit was elevated at 2.25 IU/L (reference range, 0.09 to 0.4); luteinizing hormone was normal at 4 IU/L (reference range, 1 to 10); total testosterone was low at 6.8 nmol/L (reference range, 9.5 to 35); and prolactin was slightly increased at 433 mU/L (reference range, 50 to 300). Transsphenoidal hypophysectomy was performed. Pituitary histopathologic examination showed a tumor with cytoplasmic granular FSH immunoreactivity. The patient had undergone parathyroidectomy for primary hyperparathyroidism 2 years before the current intervention. A family history of endocrine neoplasia was obtained of one sibling with a nonfunctioning pituitary adenoma, another sibling who had died of pancreatic carcinoma, and a third sibling, along with her son, who has primary hyperparathyroidism. Performance of genetic testing for MEN 1 revealed a nonsense mutation--R460X (nt7605C>T)--located on exon 10 of the MEN1 gene.
CONCLUSION: We report an unusual case of clearly high circulating immunoreactive FSH due to a functioning FSH-secreting gonadotroph adenoma in a man with the MEN 1 syndrome.